Competitive Technologies Enters Joint Ventures With Xion

September 11, 2009 (FinancialWire) — Competitive Technologies, Inc. (NYSE AMEX: CTT) has entered into a joint venture with XION Corp. for the research, development and commercialization of its patented melanocortin analogue compounds which have shown promise in treating sexual dysfunction and obesity.

Ownership in the joint venture will be divided equally between CTT and XION. Peptide analogues of alpha-MSH (alpha-melanocyte-stimulating hormone), were invented by a team of researchers at CTT’s client, the University of Arizona.

“The melanocortin analogue technology has long been a valuable part of CTT’s portfolio of innovative technologies,” said John B. Nano, CTT’s chairman, president and CEO. “CTT’s goal is to maximize the value and to protect the rightful interests of our clients, the University of Arizona and the inventors, and of our shareholders.”

Nano added, “CTT continues to aggressively market its portfolio of technologies to drive revenue growth, improve profitability and create shareholder value. Technologies include CTT’s pain therapy medical device that treats chronic neuropathic and oncologic pain, including pain resistant to morphine and other narcotic pain killers. CTT has installations at several prestigious medical centers and is in the process of adding additional medical centers to treat patients with CTT’s pain therapy.” For more information on CTT’s pain therapy, visit

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site ( Contact FinancialWire(tm) directly via

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (

Powered by EIN Presswire